ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Atypical antidepressants: Pharmacokinetics

Atypical antidepressants: Pharmacokinetics
Drug Bioavailability
(%)
Time to peak plasma concentration
(hours)
Primary metabolism* Active metabolite(s) Elimination half-life
(hours)
Effect on drug metabolism
(significant)*
Clearance
Agomelatine

<5

Wide inter-individual variation; unaffected by food
1 to 2

CYP1A2

Avoid use with moderate or strong inhibitors of CYP1A2
No 1 to 2 None Hepatic; avoid use in setting of hepatic impairment or active liver disease
Bupropion Not available; modestly increased by food

Immediate release: 2

Sustained release: 3

Extended release: 5

CYP2B6

UGT glucuronidation
Yes (hydroxybupropion and others)

14 (parent, immediate release)

20 (parent, extended release)

21-51 (active metabolites)
Inhibits CYP2D6 (strong) Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency
Mirtazapine

50

Unaffected by food
2

CYP1A2

CYP2D6

CYP3A4
Yes (N-desmethyl mirtazapine)

20 to 40 (parent)

25 (active metabolite)

T ½ and serum concentrations are increased in female and older subjects
None Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency
These classifications are based upon US Food and Drug Administration (FDA) guidance.[1,2] Other sources may use a different classification system resulting in some agents being classified differently.

CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase.

* Drug interactions and management suggestions may be determined by use of the drug interactions program included within UpToDate.

¶ Not available in the United States.
References:
  1. US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (Accessed on June 5, 2020).
  2. US Food & Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/.

Data from: UpToDate Lexidrug. More information available at https://online.lexi.com/.

Additional data from:
  1. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.
  2. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685.
  3. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.
  4. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23:427.
Graphic 88061 Version 15.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟